Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $718.54 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABIOMED | $279.75 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $135.00 | 1 | $0 (2022) |
| Merck Sharp & Dohme LLC | $124.29 | 1 | $0 (2023) |
| Melinta Therapeutics, LLC | $78.65 | 1 | $0 (2023) |
| Becton, Dickinson and Company | $52.19 | 1 | $0 (2024) |
| La Jolla Pharmaceutical Company | $28.62 | 2 | $0 (2019) |
| Chiesi USA, Inc. | $20.04 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52.19 | 1 | Becton, Dickinson and Company ($52.19) |
| 2023 | $202.94 | 2 | Merck Sharp & Dohme LLC ($124.29) |
| 2022 | $273.81 | 2 | ABIOMED ($138.81) |
| 2021 | $140.94 | 1 | ABIOMED ($140.94) |
| 2019 | $28.62 | 2 | La Jolla Pharmaceutical Company ($28.62) |
| 2017 | $20.04 | 1 | Chiesi USA, Inc. ($20.04) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Becton, Dickinson and Company | PowerPICC (Device) | Food and Beverage | In-kind items and services | $52.19 | General |
| Category: Vascular Access Devices | ||||||
| 09/26/2023 | Melinta Therapeutics, LLC | Vabomere (Drug) | Food and Beverage | In-kind items and services | $78.65 | General |
| Category: ANTIBIOTICS | ||||||
| 02/23/2023 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $124.29 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/29/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 03/22/2022 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $138.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/07/2021 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $140.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/12/2019 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: GIAPREZA | ||||||
| 07/24/2019 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: GIAPREZA | ||||||
| 08/16/2017 | Chiesi USA, Inc. | KENGREAL (Drug) | Food and Beverage | Cash or cash equivalent | $20.04 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 116 | 373 | $229,499 | $59,254 |
| 2022 | 3 | 95 | 351 | $221,331 | $57,938 |
| 2021 | 3 | 128 | 384 | $233,646 | $64,270 |
| 2020 | 2 | 203 | 534 | $337,646 | $93,529 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 84 | 327 | $219,793 | $56,357 | 25.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 46 | $9,706 | $2,897 | 29.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 69 | 317 | $212,636 | $55,604 | 26.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 21 | $4,431 | $1,173 | 26.5% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 11 | 13 | $4,264 | $1,160 | 27.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 93 | 340 | $222,360 | $61,110 | 27.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 22 | $6,644 | $1,863 | 28.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 22 | $4,642 | $1,296 | 27.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 175 | 502 | $327,982 | $90,858 | 27.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 32 | $9,664 | $2,671 | 27.6% |
About Dr. Faisal Uddin, M.D
Dr. Faisal Uddin, M.D is a Pulmonary Disease healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1750541041.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Faisal Uddin, M.D has received a total of $718.54 in payments from pharmaceutical and medical device companies, with $52.19 received in 2024. These payments were reported across 9 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($718.54).
As a Medicare-enrolled provider, Uddin has provided services to 542 Medicare beneficiaries, totaling 1,642 services with total Medicare billing of $274,990. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Internal Medicine
- Location Houston, TX
- Active Since 06/11/2008
- Last Updated 02/24/2014
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1750541041
Products in Payments
- Impella (Device) $279.75
- RECARBRIO (Drug) $124.29
- Vabomere (Drug) $78.65
- PowerPICC (Device) $52.19
- GIAPREZA (Drug) $28.62
- KENGREAL (Drug) $20.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Houston
Nicola Hanania, Md, MD
Pulmonary Disease — Payments: $1.3M
Dr. Howard Huang, Md, MD
Pulmonary Disease — Payments: $314,825
Dr. Alexander Stadnyk, M.d, M.D
Pulmonary Disease — Payments: $209,005
Adaani Frost, Md, MD
Pulmonary Disease — Payments: $88,576
Phuong-Dung Nguyen, Md, MD
Pulmonary Disease — Payments: $73,106
Dr. Kiran Nair, D.o, D.O
Pulmonary Disease — Payments: $47,551